These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 36036751)

  • 1. Clinical outcomes of PD Check-In, a model for supported self-managed maintenance of speech in Parkinson's disease: A Phase 1 study.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2023 Mar; 58(2):241-255. PubMed ID: 36036751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD Check-In: The development and trial of a supported self-management program for people with Parkinson's disease following intensive speech intervention.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2022 Jan; 57(1):138-151. PubMed ID: 34767290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of PD Check-In on self-management skills for maintenance of speech after intensive treatment.
    Finnimore A; Theodoros D; Rumbach AF
    Int J Lang Commun Disord; 2024; 59(4):1628-1646. PubMed ID: 38377119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intensive voice treatment (LSVT®LOUD) for Parkinson's disease following deep brain stimulation of the subthalamic nucleus.
    Spielman J; Mahler L; Halpern A; Gilley P; Klepitskaya O; Ramig L
    J Commun Disord; 2011; 44(6):688-700. PubMed ID: 21724193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of PD Check-In, a Model for Supported Self-Managed Maintenance of Speech on the Quality of Life of People with Parkinson's Disease: A Phase 1 Study.
    Finnimore A; Theodoros D; Rumbach A
    Brain Sci; 2022 Mar; 12(4):. PubMed ID: 35447964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Intensive Voice Treatment (The Lee Silverman Voice Treatment [LSVT LOUD]) in Subjects With Multiple Sclerosis: A Pilot Study.
    Baldanzi C; Crispiatico V; Foresti S; Groppo E; Rovaris M; Cattaneo D; Vitali C
    J Voice; 2022 Jul; 36(4):585.e1-585.e13. PubMed ID: 32819780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Speech treatment in Parkinson's disease: Randomized controlled trial (RCT).
    Ramig L; Halpern A; Spielman J; Fox C; Freeman K
    Mov Disord; 2018 Nov; 33(11):1777-1791. PubMed ID: 30264896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respiratory Responses to Two Voice Interventions for Parkinson's Disease.
    Richardson K; Huber JE; Kiefer B; Kane C; Snyder S
    J Speech Lang Hear Res; 2022 Oct; 65(10):3730-3748. PubMed ID: 36167066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lee Silverman voice treatment versus NHS speech and language therapy versus control for dysarthria in people with Parkinson's disease (PD COMM): pragmatic, UK based, multicentre, three arm, parallel group, unblinded, randomised controlled trial.
    Sackley CM; Rick C; Brady MC; Woolley R; Burton C; Patel S; Masterson-Algar P; Nicoll A; Smith CH; Jowett S; Ives N; Beaton G; Dickson S; Ottridge R; Sharp L; Nankervis H; Clarke CE;
    BMJ; 2024 Jul; 386():e078341. PubMed ID: 38986549
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Lee Silverman Voice Treatment (LSVT LOUD®) on swallowing and cough in Parkinson's disease: A pilot study.
    Miles A; Jardine M; Johnston F; de Lisle M; Friary P; Allen J
    J Neurol Sci; 2017 Dec; 383():180-187. PubMed ID: 29246611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Communicative participation outcomes in individuals with Parkinson's disease receiving standard care speech-language therapy services in community settings.
    Baylor C; Linna Jin J; Mach H; Britton D
    Int J Lang Commun Disord; 2024; 59(2):808-827. PubMed ID: 37855252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of Lee Silverman Voice Treatment® LOUD on Japanese-Speaking Patients with Parkinson's Disease.
    Nakayama K; Yamamoto T; Oda C; Sato M; Murakami T; Horiguchi S
    Rehabil Res Pract; 2020; 2020():6585264. PubMed ID: 32411475
    [No Abstract]   [Full Text] [Related]  

  • 13. The impact of Lee Silverman Voice Treatment (LSVT LOUD®) on voice, communication, and participation: Findings from a prospective, longitudinal study.
    Bryans LA; Palmer AD; Anderson S; Schindler J; Graville DJ
    J Commun Disord; 2021; 89():106031. PubMed ID: 33259945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delivering group speech maintenance therapy via telerehabilitation to people with Parkinson's disease: A pilot study.
    Quinn R; Park S; Theodoros D; Hill AJ
    Int J Speech Lang Pathol; 2019 Aug; 21(4):385-394. PubMed ID: 29879854
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of an extended version of the lee silverman voice treatment on voice and speech in Parkinson's disease.
    Spielman J; Ramig LO; Mahler L; Halpern A; Gavin WJ
    Am J Speech Lang Pathol; 2007 May; 16(2):95-107. PubMed ID: 17456888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neural correlates of efficacy of voice therapy in Parkinson's disease identified by performance-correlation analysis.
    Narayana S; Fox PT; Zhang W; Franklin C; Robin DA; Vogel D; Ramig LO
    Hum Brain Mapp; 2010 Feb; 31(2):222-36. PubMed ID: 19639554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating disordered speech and voice in Parkinson's disease online: a randomized controlled non-inferiority trial.
    Constantinescu G; Theodoros D; Russell T; Ward E; Wilson S; Wootton R
    Int J Lang Commun Disord; 2011; 46(1):1-16. PubMed ID: 21281410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intensive voice treatment (LSVT) for patients with Parkinson's disease: a 2 year follow up.
    Ramig LO; Sapir S; Countryman S; Pawlas AA; O'Brien C; Hoehn M; Thompson LL
    J Neurol Neurosurg Psychiatry; 2001 Oct; 71(4):493-8. PubMed ID: 11561033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Acoustic Voice Quality Index (AVQI) in People with Parkinson's Disease Before and After Intensive Voice and Articulation Therapies: Secondary Outcome of a Randomized Controlled Trial.
    Moya-Galé G; Spielman J; Ramig LA; Campanelli L; Maryn Y
    J Voice; 2024 Nov; 38(6):1529.e7-1529.e16. PubMed ID: 35450735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.